Skip to content

US · AARD · BIOTECHNOLOGY

Aardvark Therapeutics, Inc. Common Stock (AARD) intrinsic value and stock valuation

$0.92as of 2026-11-21 · Mkt cap 164.57M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Aardvark Therapeutics, Inc. Common Stock DCF and intrinsic value

InvestorsCraft values AARD with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from AARD’s statements →

Aardvark Therapeutics, Inc. Common Stock Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Diego, CA 92122 aardvarktherapeutics.com

How the business is doing

Fiscal 2022–2025, USD

Revenue
$0.00
20222025
Net income
-$-57.59M
20222025
Free cash flow
-$-54.27M
20222025
Total equity
$106.6M
20222025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2022–2025, USD
2025202420232022
Revenue$0.00$0.00$0.00$0.00
Operating income-$-62.73M-$-22.79M-$-7.42M-$-11.36M
Net income-$-57.59M-$-20.59M-$-7.21M-$-13.56M
EPSd-$-2.64M-$-948.85K-$-337.23K-$-634.24K
Operating cash flow-$-54.17M-$-18.09M-$-5.82M-$-10.54M
Capital expenditure-$-100K-$-110K$0.00$0.00
Free cash flow-$-54.27M-$-18.2M-$-5.82M-$-10.54M
Total assets$117.2M$77.5M$10.5M$16.8M
Total debt$440K$780K$160K$260K
Net debt-$-46.61M-$-60.86M-$-9.57M-$-15.3M
Total equity$106.6M-$-54.64M-$-34.8M-$-27.92M
Cash and short-term investments$110M$73.7M$9.99M$16.1M
Income statement
2025202420232022
Revenue$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00
Research and development expenses$48.9M$17.4M$4.48M$7.17M
Selling, general and administrative expenses$13.8M$5.3M$2.17M$2.7M
Other expenses$0.00$120K$760K$1.49M
Operating expenses$62.7M$22.8M$7.42M$11.4M
Cost and expenses$62.7M$22.8M$7.42M$11.4M
Interest income$5.14M$2.41M$1.42M$120K
Interest expense$0.00$0.00$0.00$0.00
Depreciation and amortization$40K$20K$100K$110K
Ebitda-$-57.55M-$-22.65M-$-6.56M-$-10.76M
Operating income-$-62.73M-$-22.79M-$-7.42M-$-11.36M
Total other income/expenses, net$5.13M$2.2M$210K-$-2.2M
Income before tax-$-57.59M-$-20.59M-$-7.21M-$-13.56M
Income tax expense$0.00$0.00$0.00$0.00
Net income-$-57.59M-$-20.59M-$-7.21M-$-13.56M
Weighted average shares outstanding$21.8M$21.7M$21.4M$21.4M
Weighted average diluted shares outstanding$21.8M$21.7M$21.4M$21.4M
Balance sheet
2025202420232022
Cash and short-term investments$110M$73.7M$9.99M$16.1M
Net receivables$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00
Total current assets$111.9M$74.1M$10.4M$16.5M
Property, plant and equipment, net$350K$730K$150K$250K
Goodwill and intangible assets$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00
Total non-current assets$5.29M$3.37M$170K$270K
Total assets$117.2M$77.5M$10.5M$16.8M
Accounts payable$2.07M$2.3M$1.03M$260K
Short-term debt$440K$340K$110K$100K
Deferred revenue$0.00$0.00$0.00$0.00
Total current liabilities$10.6M$4.93M$1.38M$590K
Long-term debt$0.00$440K$50K$160K
Deferred revenue, non-current$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$127.2M$44M$44.1M
Capital lease obligations$440K$780K$160K$260K
Total liabilities$10.6M$132.2M$45.3M$44.7M
Common stock$0.00$0.00$0.00$0.00
Retained earnings-$-115.92M-$-58.33M-$-37.74M-$-30.53M
Accumulated other comprehensive income (loss)$80K$0.00$0.00$0.00
Total equity$106.6M-$-54.64M-$-34.8M-$-27.92M
Total investments$63M$12M$250K$550K
Total debt$440K$780K$160K$260K
Net debt-$-46.61M-$-60.86M-$-9.57M-$-15.3M
Cash flow statement
2025202420232022
Net income-$-57.59M-$-20.59M-$-7.21M-$-13.56M
Depreciation and amortization-$-1.31M$20K$100K$110K
Stock-based compensation$3.95M$440K$310K$410K
Change in working capital$360K$1.57M-$-80K-$-1.31M
Accounts receivable$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00
Accounts payable$240K$800K$780K$30K
Net cash provided by operating activities-$-54.17M-$-18.09M-$-5.82M-$-10.54M
Investments in property, plant and equipment-$-100K-$-110K$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-49.67M-$-12M$0.00-$-1M
Common stock issued$89.3M$330K$0.00$230K
Common stock repurchased$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00
Net cash used for financing activities$89.3M$82M$0.00$230K
Net change in cash-$-14.59M$51.9M-$-5.82M-$-11.32M
Cash at end of period$47.1M$61.6M$9.73M$15.6M
Operating cash flow-$-54.17M-$-18.09M-$-5.82M-$-10.54M
Capital expenditure-$-100K-$-110K$0.00$0.00
Free cash flow-$-54.27M-$-18.2M-$-5.82M-$-10.54M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Aardvark Therapeutics, Inc. Common Stock

        Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.

        CEO
        Tien-Li Lee
        Employees
        40
        Beta
        3.81

        Explore

        Frequently asked questions

        What is the intrinsic value of Aardvark Therapeutics, Inc. Common Stock (AARD)?

        InvestorsCraft does not currently publish an intrinsic value for AARD. How the IC value is calculated.

        Is AARD undervalued?

        InvestorsCraft does not publish an undervaluation signal for AARD at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.